Zhu H - Search Results

1

Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes.

Xiao L, Li Y, Hong C, Ma P, Zhu H, Cui H, Zou X, Wang J, Li R, He J, Liang S, Li Z, Zeng L, Liu L. Xiao L, et al. Among authors: zhu h. J Transl Med. 2024 Jul 12;22(1):650. doi: 10.1186/s12967-024-05478-z. J Transl Med. 2024. PMID: 38997780 Free PMC article.

2

Association between fatty liver index and controlled attenuation parameters as markers of metabolic dysfunction-associated fatty liver disease and bone mineral density: observational and two-sample Mendelian randomization studies.

Zeng L, Li Y, Hong C, Wang J, Zhu H, Li Q, Cui H, Ma P, Li R, He J, Zhu H, Liu L, Xiao L. Zeng L, et al. Among authors: zhu h. Osteoporos Int. 2024 Apr;35(4):679-689. doi: 10.1007/s00198-023-06996-0. Epub 2024 Jan 15. Osteoporos Int. 2024. PMID: 38221591

3

Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors.

Xiao LS, Li QM, Hu CY, Cui H, Hong C, Huang CY, Li RN, Dong ZY, Zhu HB, Liu L. Xiao LS, et al. Among authors: zhu hb. Ann Palliat Med. 2021 Nov;10(11):11244-11254. doi: 10.21037/apm-21-2023. Epub 2021 Oct 11. Ann Palliat Med. 2021. PMID: 34670386 Free article.

4

Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors.

Xiao LS, Hu CY, Cui H, Li RN, Hong C, Li QM, Huang CY, Dong ZY, Zhu HB, Liu L. Xiao LS, et al. Among authors: zhu hb. Cancer Med. 2022 Dec;11(24):4880-4888. doi: 10.1002/cam4.4818. Epub 2022 May 23. Cancer Med. 2022. PMID: 35599583 Free PMC article.

5

Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: a retrospective cohort study.

Xiao LS, Li RN, Cui H, Hong C, Huang CY, Li QM, Hu CY, Dong ZY, Zhu HB, Liu L. Xiao LS, et al. Among authors: zhu hb. BMC Cancer. 2022 Jul 6;22(1):737. doi: 10.1186/s12885-022-09823-7. BMC Cancer. 2022. PMID: 35794525 Free PMC article.

6

Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors.

Hong C, Dong HZ, Li RN, Zhu HB, Li QM, Cui H, Hu CY, Huang CY, Peng J, Liu L, Zou XJ, Xiao LS. Hong C, et al. Among authors: zhu hb. Dig Dis. 2023;41(3):422-430. doi: 10.1159/000527574. Epub 2022 Oct 18. Dig Dis. 2023. PMID: 36257291

7

Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study.

Xiao L, Liao Y, Wang J, Li Q, Zhu H, Hong C, Li R, He J, Cui H, Dong H, Zeng L, Liu L. Xiao L, et al. Among authors: zhu h. Cancer Immunol Immunother. 2023 Jul;72(7):2299-2308. doi: 10.1007/s00262-023-03417-3. Epub 2023 Mar 8. Cancer Immunol Immunother. 2023. PMID: 36884079 Free PMC article.

8

Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study.

Li QM, Sun QC, Jian Y, He JZ, Zhu HB, Hong C, Zeng L, Li RN, Wang JR, Li Y, Chen LY, Weng X, Liu L, Dong HZ, Xiao LS, Cui H. Li QM, et al. Among authors: zhu hb. Discov Oncol. 2023 Jun 19;14(1):105. doi: 10.1007/s12672-023-00708-0. Discov Oncol. 2023. PMID: 37336826 Free PMC article.

9

Lower creatinine to cystatin C ratio is associated with an increased risk of MASLD: A cross-sectional and prospective study of 368,634 UK Biobank participants.

Wang J, Zeng L, Hong C, Cui H, Wang W, Zhu H, Li Q, Li Y, Li R, He J, Zhu H, Liu L, Xiao L. Wang J, et al. Among authors: zhu h. Clin Endocrinol (Oxf). 2024 Feb;100(2):116-123. doi: 10.1111/cen.14990. Epub 2023 Dec 26. Clin Endocrinol (Oxf). 2024. PMID: 38146598

10

CT images-based 3D convolutional neural network to predict early recurrence of solitary hepatocellular carcinoma after radical hepatectomy.

Cui H, Wang KY, Li WY, Zhu HB, Xiao LS, Liu L. Cui H, et al. Among authors: zhu hb. Diagn Interv Radiol. 2022 Nov;28(6):524-531. doi: 10.5152/dir.2022.201097. Diagn Interv Radiol. 2022. PMID: 36287132 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30,335 results

Search Page

Filters